Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma

作者
Josephzore Wk,Joseph A. D’Alessio,Padmaja Yerramilli-Rao,John Blankenship,Kathrin Buntin,Matthew Burger,Zhuoliang Chen,Young Shin Cho,John Davis,Nicolas Ebel,Jochen Eisfeld,Anne Haberkorn,Dominik Hainzl,Keith A. Hoffmaster,Matthias Napp,Dominik Pistorius,Vivek Rauniyar,Aimee Reynolds,Vincent Romanet,Christian Schnell
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:23 (12_Supplement): IA022-IA022 被引量:4
标识
DOI:10.1158/1538-8514.cancerchem24-ia022
摘要

Abstract Activating mutations in GNAQ/GNA11, encoding the G protein α subunits Gq and G11, are the most frequent genetic alterations in uveal melanoma (UVM) and considered to be critical for the initiation and maintenance of this malignancy. Despite inhibitors of Gq and G11 exhibiting promising preclinical anti-uveal melanoma activity, their therapeutic potential is limited by on-target toxicities associated with the ubiquitous expression and critical biological processes mediated by these G proteins. Here we report the discovery of a novel Gq/11 inhibitor-based antibody-drug-conjugate (ADC), DYP688, that selectively targets UVM cells, while sparing normal Gq/11-dependent cells. This conjugate consists of the highly potent and selective Gq/11 inhibitor SDZ475 (FR900359) conjugated to an antibody targeting PMEL17, a lineage gene having significant differential expression in melanoma. DYP688 potently inhibits Gq/11 oncogenic signaling, resulting in selective antiproliferative activity and apoptosis in PMEL17-positive, GNAQ/11-mutant UVM cells. In vivo, DYP688 exhibits marked and durable tumor regression in GNAQ/11-mutant UVM models, including patient-derived xenograft and liver metastasis models. Finally, we show that DYP688 features favorable preclinical pharmacokinetic and safety profiles, supportive of clinical evaluation. A phase 1 clinical trial with DYP688 is currently ongoing to assess the safety, tolerability and preliminary anti-tumor activity in patients with metastatic UVM and other GNAQ/11-mutant melanomas (clinicaltrials.gov identifier NCT05415072). Citation Format: Josephzore Wk, Joseph A. D'Alessio, Padmaja Yerramilli-Rao, John Blankenship, Kathrin Buntin, Matthew Burger, Zhuoliang Chen, Young Shin Cho, John Davis, Nicolas Ebel, Jochen Eisfeld, Anne Haberkorn, Dominik Hainzl, Keith Hoffmaster, Matthias Napp, Dominik Pistorius, Vivek Rauniyar, Aimee Reynolds, Vincent Romanet, Christian Schnell, Katherine Seiss, William R. Tschantz, Susanne Wieland-Berghausen, Laurin Wimmer, Kuno Wuersch, Alan Zhang, Eusebio Manchado. DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry; 2024 Dec 9-11; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(12_Suppl):Abstract nr IA022.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
throb发布了新的文献求助10
刚刚
零零1完成签到 ,获得积分10
1秒前
碎觉觉发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
Nuyoah完成签到 ,获得积分10
4秒前
转复窦律完成签到,获得积分10
4秒前
粗犷的翎完成签到,获得积分10
4秒前
可爱安荷发布了新的文献求助10
5秒前
7秒前
cyy完成签到,获得积分10
7秒前
7秒前
啊汪~发布了新的文献求助10
9秒前
10秒前
throb完成签到,获得积分10
10秒前
大模型的应助被七听采纳,获得10
10秒前
方圆完成签到 ,获得积分10
12秒前
12秒前
遇见完成签到,获得积分20
13秒前
13秒前
2275523154完成签到,获得积分10
13秒前
千里清秋完成签到,获得积分10
13秒前
quan完成签到,获得积分10
13秒前
美宁完成签到,获得积分10
15秒前
顺利的妖妖完成签到 ,获得积分10
16秒前
再睡十分钟完成签到 ,获得积分10
16秒前
penicillin完成签到 ,获得积分10
16秒前
辛勤以柳发布了新的文献求助10
18秒前
敏感的傲云完成签到,获得积分10
18秒前
18秒前
xiahaijun发布了新的文献求助10
19秒前
19秒前
情怀的应助被七听采纳,获得10
20秒前
李明明完成签到,获得积分10
20秒前
21秒前
微血管完成签到,获得积分10
21秒前
yyy完成签到,获得积分10
21秒前
大胆的初瑶完成签到,获得积分10
21秒前
以后完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190478
求助须知:如何正确求助?哪些是违规求助? 9577686
关于积分的说明 21853808
捐赠科研通 7789496
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483054